Schedule 13D ownership disclosure

ESSA PHARMA INC

Common Shares · CUSIP: 29668H708

Event date: 2025-10-09

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • BIOTECHNOLOGY VALUE FUND L PReported CIK 0000918923

    Shares: 0.00 · Class: 0%

  • BVF I GP LLCReported CIK 0001803805

    Shares: 0.00 · Class: 0%

  • BIOTECHNOLOGY VALUE FUND II LPReported CIK 0001102444

    Shares: 0.00 · Class: 0%

  • BVF II GP LLCReported CIK 0001803806

    Shares: 0.00 · Class: 0%

  • Biotechnology Value Trading Fund OS LPReported CIK 0001660683

    Shares: 0.00 · Class: 0%

  • BVF Partners OS Ltd.Reported CIK 0001660684

    Shares: 0.00 · Class: 0%

  • BVF GP HOLDINGS LLCReported CIK 0001803809

    Shares: 0.00 · Class: 0%

  • BVF PARTNERS L P/ILReported CIK 0001055947

    Shares: 0.00 · Class: 0%

  • BVF INC/ILReported CIK 0001056807

    Shares: 0.00 · Class: 0%

  • LAMPERT MARK NReported CIK 0001233840

    Shares: 0.00 · Class: 0%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000921895-25-002741
Form type
SCHEDULE 13D/A
Filer
BIOTECHNOLOGY VALUE FUND L P
CIK
CIK 918923
Filed
Oct 14, 2025
Reporting period
Oct 09, 2025
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub